von Willebrand factor: What is its role in the immune response in haemophilia?

Haemophilia

Volumn 17, Issue 1, 2011, Pages

  Kaveri, S ^a   Mannucci, P M ^b   Kurth, M H ^c   Ewing, N ^d   Kessler, C M ^e   Nugent, D J ^f   Gomperts, E D ^g  

^a INSERM   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR;

ARTICLE; HEMOPHILIA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MICE; VON WILLEBRAND FACTOR;

EID: 78049262621     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02277.x     Document Type: Article

References (38)

1. White GC, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
2. Kreuz W, Ettingshausen CE, Auerswald G et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
3. Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX. An introductory discussion for physicians. In: Schulman S ed. Treatment of Hemophilia Monograph Series. Published September 2004, no. 34. Available at Accessed April 7, 2010.
4. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
5. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(Suppl. 6): 15-22.
6. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
7. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
8. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
9. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
10. Lusher J, Abildgaard C, Arkin S et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574-83.
11. Aledort LM, DiMichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
12. Kaveri SV, Dasgupta S, Andre S et al. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells. Haemophilia 2007; 13(Suppl. 5): 61-4.
13. Dasgupta S, Repesse Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.
14. Lacroix-Desmazes S, Repesse Y, Kaveri SV, Dasgupta S. The role of VWF in the immunogenicity of FVIII. Thromb Res 2008; 122(Suppl. 2): S3-6.
15. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
16. Delignat S, Dasgupta S, Andre S et al. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 2007; 92: 1423-6.
17. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
18. Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
19. Gouw SC, van der Bom JG, Auerswald G et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7.
20. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13: 65-8.
21. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variataion in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996; 2: 95-9.
22. Berntorp E. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance? Haematologica 2003; 88: EREP03.
23. Berntorp E. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice. Haemophilia 2007; 13(Suppl. 5): 69-72.
24. Gensana M, Altisent C, Aznar JA et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369-74.
25. Astermark J, Voorberg J, Lenk H et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-72.
26. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375-80.
27. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
28. Tagariello G, Zanotto D, Radossi P et al. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 2007; 82: 460-2.
29. Salvagno GL, Astermark J, Ekman M et al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 51-6.
30. Inoue T, Shima M, Takeyama M et al. Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor. Haemophilia 2006; 12: 110-3.
31. Kreuz W, Joseph-Steiner J, Mentzer D et al. Successful immune tolerance therapy of factor VIII inhibitors in children after changing from high to intermediate purity factor VIII concentrate. Ann Hematol 1996; 72(Suppl. 1): 339.
32. Kaveri S, Gringeri A, Heisel-Kurth M, Kreuz W. Inhibitors in hemophilia A: the role of VWF/FVIII concentrates. Haemophilia 2008; 15: 587-91.
33. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
34. Orsini F, Rothschild C, Beurrier P et al. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
35. Gringeri A, Musso R, Mazzucconi MG et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
36. Kurth MAH, DiMichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-5.
37. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
38. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.